The new study “is a big deal and has been the buzz of the breast cancer research world,” said Dr. Larry Norton of Memorial Sloan Kettering Cancer Center in an email. He said he has received consulting fees from about 10 drug companies, including Genentech. The women in the study had triple-negative breast cancer that had been newly diagnosed and had become metastatic, meaning it had begun to spread. Half received chemo alone, and half were given chemo plus immunotherapy. Among those who received the combination, the median survival was 21.3 months, compared with 17.6 months for those who received chemo alone.

Source: New York Times October 20, 2018 14:26 UTC